论文部分内容阅读
[目的]探讨晚期胸腺癌的临床病理特点及预后。[方法]回顾性分析19例经病理或细胞学检查证实的晚期胸腺癌患者的临床病理资料。[结果]鳞癌占全部患者的63.2%。全组患者3年生存率为46.7%。手术患者与非手术患者的3年生存率分别为83.3%和22.2%(P<0.05)。完整切除与未完整切除(包括部分切除和手术探查)的患者3年生存率分别为100.0%和60.0%(P>0.05)。放疗患者与非放疗患者的3年生存率分别为50.0%和33.3%(P>0.05)。Ⅲ期与Ⅳ期患者的3年生存率分别为71.4%和25.0%(P>0.05)。高分化癌(鳞癌)和低分化癌(神经内分泌癌、未分化癌)的3年生存率分别是50.0%和42.9%(P>0.05)。[结论 ]鳞癌是最常见的胸腺癌病理亚型。晚期胸腺癌患者应尽可能完整手术切除,术后辅以放化疗。手术切除、WHO病理分型影响胸腺癌患者预后。
[Objective] To investigate the clinicopathological features and prognosis of advanced thymic carcinoma. [Methods] The clinical and pathological data of 19 patients with advanced thymic carcinoma proved by pathology or cytology were retrospectively analyzed. [Results] Squamous cell carcinoma accounted for 63.2% of all patients. The 3-year overall survival rate was 46.7%. The 3-year survival rates of surgical patients and non-surgical patients were 83.3% and 22.2%, respectively (P <0.05). The 3-year survival rates of patients with complete resection and incomplete resection (including partial resection and surgical exploration) were 100.0% and 60.0%, respectively (P> 0.05). The 3-year survival rates of patients in radiotherapy and non-radiotherapy were 50.0% and 33.3% respectively (P> 0.05). The 3-year survival rates of stage III and stage IV patients were 71.4% and 25.0%, respectively (P> 0.05). The 3-year survival rates of well differentiated carcinoma (squamous cell carcinoma) and poorly differentiated carcinoma (neuroendocrine carcinoma, undifferentiated carcinoma) were 50.0% and 42.9%, respectively (P> 0.05). [Conclusion] Squamous cell carcinoma is the most common pathological subtype of thymus cancer. Patients with advanced thymic cancer should be as complete as possible surgery, postoperative radiotherapy and chemotherapy. Surgical resection, WHO pathological classification of patients with thymic cancer prognosis.